AUS
NZ
UK
CA
USA
IND
Roquefort Therapeutics PLC, a company operating within the Healthcare sector, has achieved a significant milestone with the European Patent Office granting a patent for its Mesodermal Killer (MK) cell therapy. This patent provides intellectual property protection across 39 countries, including the UK and the EU, strengthening Roquefort's position in the expanding field of cell-based immunotherapy.
Patent Coverage and Therapeutic Potential
The granted patent covers Roquefort's MK cell therapy, an off-the-shelf cellular medicine designed to enhance immunotherapy approaches. MK cells have demonstrated the ability to activate natural killer (NK) cells effectively, with early pre-clinical testing showing up to a two-fold increase in cytotoxicity when compared to NK cells alone. These preliminary findings highlight the potential applications of MK cells in treating various conditions within immunology and oncology.
Advancement of the MK Cell Programme
Roquefort Therapeutics PLC (LSE:ROQ) is preparing to advance its MK cell programme through in vivo studies, aiming to validate the effectiveness of MK cells in activating NK cells for targeted treatments in cancer and immunology. These studies represent a critical phase in the programme's development and are expected to lay the groundwork for future clinical trials. The successful progression of these studies would mark a key inflection point, potentially accelerating the transition from pre-clinical to clinical stages.
Out-Licensing Strategy and Additional Programmes
Alongside the MK cell programme, Roquefort Therapeutics is also pursuing an out-licensing strategy to maximise its portfolio's value. The company is in active discussions with PDC FZ-LLC to finalise the out-licensing of its Midkine antibody portfolio. Furthermore, Roquefort is exploring partnership opportunities with major pharmaceutical companies for its STAT-6 siRNA programme, aiming to expand its reach within the biotech landscape.
Additional in vitro experiments are currently underway in an immunology context, with results expected to further support the MK cell programme's appeal to potential licensees. The company anticipates that positive outcomes from these experiments will enhance the programme’s attractiveness and facilitate ongoing discussions with industry partners.
CEO Comments on Patent Grant and Market
Commenting on the European patent grant, Roquefort Therapeutics CEO Ajan Reginald highlighted the significance of securing foundational intellectual property for the MK cell therapy. He noted that the patent confirms the novelty of the MK cells and underscores their potential within the immunology and oncology markets. Reginald emphasized that these markets are of high interest to both large pharmaceutical companies and advanced biotech firms.
The interest in the sector is further illustrated by the recent initial public offering (IPO) of Artiva Biotherapeutics, a company specialising in natural killer cells. Artiva's IPO was oversubscribed, raising $167 million in July 2024, reflecting the growing market demand for innovative immunotherapy solutions.
Roquefort Therapeutics' progress in securing intellectual property and advancing its MK cell programme continues to position the company as a key player in the rapidly evolving field of biotechnology.
